Variations in biological and immunological activity of growth hormone during the neonatal period

S. Pagani, E. A. Chaler, G. Radetti, P. Travaglino, C. Meazza, E. Bozzola, N. Sessa, A. Belgorosky, M. Bozzola

Research output: Contribution to journalArticle

Abstract

Background/Aims: It was postulated that a high growth hormone (GH) bioactivity might explain the rapid growth rate of neonates. The aim of this study is to verify changes in serum GH biological potency (Bio-/Immuno-GH ratio) and their effects on serum growth factors during the first month of life in term and preterm babies. Methods: Blood samples were collected from 10 small-for-gestational-age preterm (SGAPT), 17 appropriate for gestational age preterm (AGAPT) and 26 AGA term (T) neonates on days 4, 15 and 30 of life to evaluate serum GH values measured by IFMA (IFMA-GH) and bioassay (Bio-GH), serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3). Results: High serum Bio-GH values on the first few days of life correspond to high IFMA-GH values, suggesting full biological potency of circulating GH. Furthermore, IGF-I/IGFBP-3 molar ratio values in preterm babies were higher than in full-term infants. Conclusions: These data confirmed the hypothesis that the higher growth velocity in the first month of life of preterm neonates is due to an increased bioavailability of IGF-I. A progressive maturation of the hypothalamic-pituitary-IGF-I axis without any alteration in the GH biological potency seems to underpin the increase of the growth factors early in life.

Original languageEnglish
Pages (from-to)145-149
Number of pages5
JournalHormone Research
Volume68
Issue number3
DOIs
Publication statusPublished - Aug 2007

Fingerprint

Growth Hormone
Insulin-Like Growth Factor I
Serum
Insulin-Like Growth Factor Binding Protein 3
Newborn Infant
Gestational Age
Intercellular Signaling Peptides and Proteins
Growth
Biological Assay
Biological Availability

Keywords

  • Growth hormone
  • Insulin-like growth factor binding protein-3
  • Insulin-like growth factor I
  • Nb2 bioassay

ASJC Scopus subject areas

  • Endocrinology

Cite this

Variations in biological and immunological activity of growth hormone during the neonatal period. / Pagani, S.; Chaler, E. A.; Radetti, G.; Travaglino, P.; Meazza, C.; Bozzola, E.; Sessa, N.; Belgorosky, A.; Bozzola, M.

In: Hormone Research, Vol. 68, No. 3, 08.2007, p. 145-149.

Research output: Contribution to journalArticle

Pagani, S, Chaler, EA, Radetti, G, Travaglino, P, Meazza, C, Bozzola, E, Sessa, N, Belgorosky, A & Bozzola, M 2007, 'Variations in biological and immunological activity of growth hormone during the neonatal period', Hormone Research, vol. 68, no. 3, pp. 145-149. https://doi.org/10.1159/000100990
Pagani, S. ; Chaler, E. A. ; Radetti, G. ; Travaglino, P. ; Meazza, C. ; Bozzola, E. ; Sessa, N. ; Belgorosky, A. ; Bozzola, M. / Variations in biological and immunological activity of growth hormone during the neonatal period. In: Hormone Research. 2007 ; Vol. 68, No. 3. pp. 145-149.
@article{8d082284b11d461da85ec555a90f7343,
title = "Variations in biological and immunological activity of growth hormone during the neonatal period",
abstract = "Background/Aims: It was postulated that a high growth hormone (GH) bioactivity might explain the rapid growth rate of neonates. The aim of this study is to verify changes in serum GH biological potency (Bio-/Immuno-GH ratio) and their effects on serum growth factors during the first month of life in term and preterm babies. Methods: Blood samples were collected from 10 small-for-gestational-age preterm (SGAPT), 17 appropriate for gestational age preterm (AGAPT) and 26 AGA term (T) neonates on days 4, 15 and 30 of life to evaluate serum GH values measured by IFMA (IFMA-GH) and bioassay (Bio-GH), serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3). Results: High serum Bio-GH values on the first few days of life correspond to high IFMA-GH values, suggesting full biological potency of circulating GH. Furthermore, IGF-I/IGFBP-3 molar ratio values in preterm babies were higher than in full-term infants. Conclusions: These data confirmed the hypothesis that the higher growth velocity in the first month of life of preterm neonates is due to an increased bioavailability of IGF-I. A progressive maturation of the hypothalamic-pituitary-IGF-I axis without any alteration in the GH biological potency seems to underpin the increase of the growth factors early in life.",
keywords = "Growth hormone, Insulin-like growth factor binding protein-3, Insulin-like growth factor I, Nb2 bioassay",
author = "S. Pagani and Chaler, {E. A.} and G. Radetti and P. Travaglino and C. Meazza and E. Bozzola and N. Sessa and A. Belgorosky and M. Bozzola",
year = "2007",
month = "8",
doi = "10.1159/000100990",
language = "English",
volume = "68",
pages = "145--149",
journal = "Hormone Research",
issn = "0301-0163",
publisher = "S. Karger AG",
number = "3",

}

TY - JOUR

T1 - Variations in biological and immunological activity of growth hormone during the neonatal period

AU - Pagani, S.

AU - Chaler, E. A.

AU - Radetti, G.

AU - Travaglino, P.

AU - Meazza, C.

AU - Bozzola, E.

AU - Sessa, N.

AU - Belgorosky, A.

AU - Bozzola, M.

PY - 2007/8

Y1 - 2007/8

N2 - Background/Aims: It was postulated that a high growth hormone (GH) bioactivity might explain the rapid growth rate of neonates. The aim of this study is to verify changes in serum GH biological potency (Bio-/Immuno-GH ratio) and their effects on serum growth factors during the first month of life in term and preterm babies. Methods: Blood samples were collected from 10 small-for-gestational-age preterm (SGAPT), 17 appropriate for gestational age preterm (AGAPT) and 26 AGA term (T) neonates on days 4, 15 and 30 of life to evaluate serum GH values measured by IFMA (IFMA-GH) and bioassay (Bio-GH), serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3). Results: High serum Bio-GH values on the first few days of life correspond to high IFMA-GH values, suggesting full biological potency of circulating GH. Furthermore, IGF-I/IGFBP-3 molar ratio values in preterm babies were higher than in full-term infants. Conclusions: These data confirmed the hypothesis that the higher growth velocity in the first month of life of preterm neonates is due to an increased bioavailability of IGF-I. A progressive maturation of the hypothalamic-pituitary-IGF-I axis without any alteration in the GH biological potency seems to underpin the increase of the growth factors early in life.

AB - Background/Aims: It was postulated that a high growth hormone (GH) bioactivity might explain the rapid growth rate of neonates. The aim of this study is to verify changes in serum GH biological potency (Bio-/Immuno-GH ratio) and their effects on serum growth factors during the first month of life in term and preterm babies. Methods: Blood samples were collected from 10 small-for-gestational-age preterm (SGAPT), 17 appropriate for gestational age preterm (AGAPT) and 26 AGA term (T) neonates on days 4, 15 and 30 of life to evaluate serum GH values measured by IFMA (IFMA-GH) and bioassay (Bio-GH), serum insulin-like growth factor-I (IGF-I) and IGF-binding protein-3 (IGFBP-3). Results: High serum Bio-GH values on the first few days of life correspond to high IFMA-GH values, suggesting full biological potency of circulating GH. Furthermore, IGF-I/IGFBP-3 molar ratio values in preterm babies were higher than in full-term infants. Conclusions: These data confirmed the hypothesis that the higher growth velocity in the first month of life of preterm neonates is due to an increased bioavailability of IGF-I. A progressive maturation of the hypothalamic-pituitary-IGF-I axis without any alteration in the GH biological potency seems to underpin the increase of the growth factors early in life.

KW - Growth hormone

KW - Insulin-like growth factor binding protein-3

KW - Insulin-like growth factor I

KW - Nb2 bioassay

UR - http://www.scopus.com/inward/record.url?scp=34547883527&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=34547883527&partnerID=8YFLogxK

U2 - 10.1159/000100990

DO - 10.1159/000100990

M3 - Article

C2 - 17377396

AN - SCOPUS:34547883527

VL - 68

SP - 145

EP - 149

JO - Hormone Research

JF - Hormone Research

SN - 0301-0163

IS - 3

ER -